The use of each medicine included in Right Breathe has been considered in relation to international, national, and regional prescribing pathways. The pathway points at which this medicine is considered a viable prescribing option are included below. If you wish to view the entire pathway, click on its heading, from where you can also access all the prescribing options for each pathway and each pathway point.
Detailed prescribing information is provided below. This content has not been generated by the RightBreathe team, but has been integrated from a 3rd party solution: Multilex (provided by FirstDataBank). Use of this prescribing content is subject to the FirstDataBank disclaimer, which is set out in the "About" section of RightBreathe.
As RightBreathe is a bespoke decision support tool, it covers each and every individual known inhaler option on the UK market to a high level of specificity. Multilex, as a more general resource, does not offer the same level of specificity. There are therefore a small number of medicines for which there are discrepancies between RightBreathe and Multilex content, most notably in relation to licensed particulars and associated licensed doses.
Given the high level of specificity the RightBreathe team work to, details of the individual inhaler licence are most likely to be summarised accurately in the content provided at the top of this page, rather than in the Multilex content below. Where there is ambiguity, users may also wish to refer to individual summaries of product characteristics prior to prescribing.
Type | Age Range | Dose | Licensed |
---|---|---|---|
Maintenance | From 5 years to 6 years | 1 actuation - TWICE a DAY - inhalation - using a metered dose device | |
Maintenance | From 6 years | 1 actuation - TWICE a DAY - inhalation - using a metered dose device | |
Maintenance | From 5 years to 6 years | 1 actuation - every EVENING - inhalation - using a metered dose device | |
Maintenance | From 6 years | 1 actuation - every EVENING - inhalation - using a metered dose device | |
Maintenance | From 12 years | 2 actuations - TWICE a DAY - inhalation - using a metered dose device | |
Maintenance | From 12 years | 2 actuations - every EVENING - inhalation - using a metered dose device |
With | Risk | Severity |
---|---|---|
RITONAVIR | Increased risk of systemic corticosteroid adverse effects | High Risk: Avoid combination. Risk outweighs benefits. |
(INDINAVIR) | Increased risk of systemic corticosteroid adverse effects | Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk. |
(NELFINAVIR) | Increased risk of systemic corticosteroid adverse effects | Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk. |
(SAQUINAVIR) | Increased risk of systemic corticosteroid adverse effects | Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk. |
(TELITHROMYCIN) | Increased risk of systemic corticosteroid adverse effects | Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk. |
APALUTAMIDE | exposure may be reduced by | Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk. |
ATAZANAVIR WITH COBICISTAT | Increased risk of systemic corticosteroid adverse effects | Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk. |
BEROTRALSTAT | plasma level may be increased by | Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk. |
CLARITHROMYCIN | Increased risk of systemic corticosteroid adverse effects | Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk. |
COBICISTAT | Increased risk of systemic corticosteroid adverse effects | Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk. |
DARUNAVIR WITH COBICISTAT | Increased risk of systemic corticosteroid adverse effects | Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk. |
DARUNAVIR, COBICISTAT, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE | Increased risk of systemic corticosteroid adverse effects | Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk. |
ELVITEGRAVIR, COBICISTAT, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE | Increased risk of systemic corticosteroid adverse effects | Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk. |
ELVITEGRAVIR, COBICISTAT, EMTRICITABINE AND TENOFOVIR DISOPROXIL | Increased risk of systemic corticosteroid adverse effects | Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk. |
IDELALISIB | Increased risk of systemic corticosteroid adverse effects | Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk. |
ITRACONAZOLE | Increased risk of systemic corticosteroid adverse effects | Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk. |
KETOCONAZOLE | Increased risk of systemic corticosteroid adverse effects | Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk. |
NEFAZODONE | Increased risk of systemic corticosteroid adverse effects | Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk. |
OMBITASVIR, PARITAPREVIR AND RITONAVIR | Increased risk of systemic corticosteroid adverse effects | Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk. |
POSACONAZOLE | Increased risk of systemic corticosteroid adverse effects | Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk. |
RIBOCICLIB | Increased risk of systemic corticosteroid adverse effects | Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk. |
TIPRANAVIR | Increased risk of systemic corticosteroid adverse effects | Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk. |
TUCATINIB | Manufacturer advises not recommended; see product literature | Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk. |
VORICONAZOLE | Increased risk of systemic corticosteroid adverse effects | Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk. |
AMPRENAVIR / FOSAMPRENAVIR | Increased risk of systemic corticosteroid adverse effects | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
APREPITANT / FOSAPREPITANT | Increased risk of systemic corticosteroid adverse effects | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
ATAZANAVIR | Increased risk of systemic corticosteroid adverse effects | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
BELZUTIFAN | plasma level may be reduced by | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
CENOBAMATE | plasma level may be reduced by | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
CICLOSPORIN | Increased risk of systemic corticosteroid adverse effects | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
CIMETIDINE | Increased risk of systemic corticosteroid adverse effects | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
CIPROFLOXACIN | Increased risk of systemic corticosteroid adverse effects | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
CRIZOTINIB | Increased risk of systemic corticosteroid adverse effects | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
DARUNAVIR | Increased risk of systemic corticosteroid adverse effects | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
DILTIAZEM | Increased risk of systemic corticosteroid adverse effects | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
DRONEDARONE | Increased risk of systemic corticosteroid adverse effects | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
ERYTHROMYCIN | Increased risk of systemic corticosteroid adverse effects | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
FLUCONAZOLE | Increased risk of systemic corticosteroid adverse effects | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
IMATINIB | Increased risk of systemic corticosteroid adverse effects | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
ISAVUCONAZOLE | Increased risk of systemic corticosteroid adverse effects | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
MICONAZOLE (ORAL AND PARENTERAL) | Increased risk of systemic corticosteroid adverse effects | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
MIFEPRISTONE | Corticosteroid effect may be reduced for 3 to 4 days after treatment | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
NETUPITANT | Increased risk of systemic corticosteroid adverse effects | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
NILOTINIB | Increased risk of systemic corticosteroid adverse effects | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
NIRMATRELVIR AND RITONAVIR | plasma level may be increased by | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
SARILUMAB | plasma level may be reduced by | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
STIRIPENTOL | Increased risk of systemic corticosteroid adverse effects | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
TELOTRISTAT | efficacy may be reduced by | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
VERAPAMIL | Increased risk of systemic corticosteroid adverse effects | Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient. |
(BOCEPREVIR) | plasma level may be increased by | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
(DACLATASVIR) | Increased risk of systemic corticosteroid adverse effects | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
(SIMEPREVIR) | Increased risk of systemic corticosteroid adverse effects | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
(TELAPREVIR) | plasma level may be increased by | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
ALPRAZOLAM | Increased risk of systemic corticosteroid adverse effects | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
AMIODARONE | Increased risk of systemic corticosteroid adverse effects | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
AMLODIPINE | Increased risk of systemic corticosteroid adverse effects | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
ATORVASTATIN | Increased risk of systemic corticosteroid adverse effects | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
AZITHROMYCIN | Increased risk of systemic corticosteroid adverse effects | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
BICALUTAMIDE | Increased risk of systemic corticosteroid adverse effects | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
CILOSTAZOL | Increased risk of systemic corticosteroid adverse effects | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
COMBINED ORAL CONTRACEPTIVES | Increased risk of systemic corticosteroid adverse effects | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
ELBASVIR WITH GRAZOPREVIR | Increased risk of systemic corticosteroid adverse effects | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
EVEROLIMUS | Increased risk of systemic corticosteroid adverse effects | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
FLUVOXAMINE | Increased risk of systemic corticosteroid adverse effects | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
ISONIAZID | Increased risk of systemic corticosteroid adverse effects | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
IVACAFTOR | Increased risk of systemic corticosteroid adverse effects | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
LACIDIPINE | Increased risk of systemic corticosteroid adverse effects | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
LINAGLIPTIN | Increased risk of systemic corticosteroid adverse effects | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
LOMITAPIDE | Increased risk of systemic corticosteroid adverse effects | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
PALBOCICLIB | Increased risk of systemic corticosteroid adverse effects | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
PAZOPANIB | Increased risk of systemic corticosteroid adverse effects | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
PEPPERMINT OIL | Increased risk of systemic corticosteroid adverse effects | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
PROPIVERINE | Increased risk of systemic corticosteroid adverse effects | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
RANITIDINE / NIZATIDINE | Increased risk of systemic corticosteroid adverse effects | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
RANOLAZINE | Increased risk of systemic corticosteroid adverse effects | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
TACROLIMUS (ORAL AND PARENTERAL) | Increased risk of systemic corticosteroid adverse effects | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
TERIFLUNOMIDE | Increased risk of systemic corticosteroid adverse effects | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |
TOLVAPTAN | Increased risk of systemic corticosteroid adverse effects | Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient. |